Recent Quotes (30 days)

You have no recent quotes
chg | %

BELLUS Health Inc  

(Public, TSE:BLU)   Watch this stock  
Find more results for BLU
1.22
+0.01 (0.83%)
May 22 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.22 - 1.22
52 week 0.85 - 1.80
Open 1.22
Vol / Avg. 8,400.00/13,886.00
Mkt cap 57.86M
P/E     -
Div/yield     -
EPS -0.03
Shares 47.43M
Beta 2.65
Inst. own     -
May 12, 2015
Q1 2015 BELLUS Health Inc Earnings Release
Feb 25, 2015
Q4 2014 BELLUS Health Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -0.89% -82.83%
Operating margin -32.57% -103.91%
EBITD margin - -103.91%
Return on average assets -0.17% -9.76%
Return on average equity -2.19% -21.35%
Employees 9 -
CDP Score - -

Address

275 Armand-Frappier Blvd
LAVAL, QC H7V 4A7
Canada
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)

Website links

Description

BELLUS Health Inc. (BELLUS Health) is engaged in developing drugs for rare diseases, starting with conditions that affect the kidneys. The Company’s lead program is KIACTA, a drug candidate in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is involved in a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body, including the kidneys, heart, liver and peripheral nerves. It is developing Shigamab, an antibody treatment for hemolytic uremic syndrome caused by Shiga toxin-producing E. coli (sHUS). Shigamab is a monoclonal antibody therapy being developed for the treatment of sHUS. It principally affects the kidneys and often leads to acute dialysis, and in certain cases chronic kidney disease and death, primarily in children.